After two failures in a row from Roche, the TIGIT hypothesis is looking shaky, but it is too early to write off the class yet.

The emergence and rapid spread of the Omicron variant has kept COVID-19 firmly in the headlines but the biopharma industry has had plenty on its plate on top of tackling the pandemic. Scrip has taken a look back at five of the biggest non-COVID-19 story themes of 2021 in no particular order.

While Amicus will transfer the gene therapy portfolio’s R&D risk to Caritas, it retains a financial interest in many of the spinout’s programs. Pompe candidate AT-GAA accepted for FDA review.

After three failures in quick succession, Merck needs to see a win in one of its many remaining Phase II trials.